PCM
PTCT icon

Prelude Capital Management’s PTC Therapeutics PTCT Stock Holding History

Prelude Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-15,228
Closed -$619K – 1306
2023
Q2 		$619K Buy
15,228
+6,939
+84% +$340K 0.04% 399
2023
Q1 		$402K Buy
+8,289
New +$379K 0.02% 534
2022
Q4 		– Sell
-4,609
Closed -$231K – 1555
2022
Q3 		$231K Buy
+4,609
New +$226K 0.01% 1014
2020
Q4 		– Sell
-1,300
Closed -$61K – 1842
2020
Q3 		$61K Sell
1,300
-7,531
-85% -$371K ﹤0.01% 1065
2020
Q2 		$448K Buy
8,831
+4,856
+122% +$239K 0.02% 495
2020
Q1 		$177K Sell
3,975
-26,192
-87% -$1.32M 0.01% 472
2019
Q4 		$1.45M Buy
30,167
+29,757
+7,258% +$1.26M 0.06% 281
2019
Q3 		$14K Sell
410
-44,163
-99% -$1.92M ﹤0.01% 1446
2019
Q2 		$2.01M Buy
44,573
+23,968
+116% +$946K 0.1% 201
2019
Q1 		$776K Buy
+20,605
New +$692K 0.04% 393
2018
Q4 		– Sell
-78,071
Closed -$3.67M – 2091
2018
Q3 		$3.67M Sell
78,071
-25,888
-25% -$1.07M 0.21% 77
2018
Q2 		$3.51M Sell
103,959
-65,004
-38% -$2.03M 0.22% 68
2018
Q1 		$4.57M Sell
168,963
-119,506
-41% -$3.03M 0.33% 48
2017
Q4 		$4.81M Buy
288,469
+107,090
+59% +$1.81M 0.39% 48
2017
Q3 		$3.63M Sell
181,379
-100,845
-36% -$1.97M 0.33% 62
2017
Q2 		$5.17M Sell
282,224
-13,971
-5% -$188K 0.49% 43
2017
Q1 		$2.92M Buy
296,195
+115,171
+64% +$1.39M 0.28% 77
2016
Q4 		$1.98M Sell
181,024
-34,947
-16% -$367K 0.24% 117
2016
Q3 		$3.03M Buy
215,971
+207,171
+2,354% +$1.68M 0.32% 54
2016
Q2 		$62K Buy
+8,800
New +$64.5K 0.01% 925
2015
Q4 		– Sell
-5,737
Closed -$153K – 1641
2015
Q3 		$153K Buy
5,737
+5,037
+720% +$215K 0.02% 700
2015
Q2 		$34K Buy
+700
New +$40.8K ﹤0.01% 1246

Other funds holding PTCT

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Prelude Capital Management's PTCT Position: Q3 2023 in Review

Prelude Capital Management sold out of PTC Therapeutics (PTCT) in Q3 2023, closing a stake of 15,228 shares — an estimated $619K sold.

Prelude Capital Management first reported a position in PTCT in Q2 2015 and held it in 22 quarters. The position peaked at $5.17M in Q2 2017. 179 funds tracked by Wall St. Rank hold PTCT as of Q3 2023.

  • Prelude Capital Management reported no remaining PTC Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Prelude Capital Management sold 15,228 PTC Therapeutics shares in Q3 2023, an estimated $619K.
  • Prelude Capital Management first reported a position in PTC Therapeutics in Q2 2015 and held it in 22 quarters.
  • Prelude Capital Management's PTC Therapeutics position peaked at $5.17M in Q2 2017.
  • 179 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2023.

Based on Prelude Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.